$2.75
12.70% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Moleculin Biotech, Inc. Stock price

$2.75
+0.28 11.34% 1M
-2.79 50.36% 6M
-10.13 78.64% YTD
-3.32 54.72% 1Y
-42.70 93.95% 3Y
-97.15 97.25% 5Y
-717.25 99.62% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.31 12.70%
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Key metrics

Market capitalization $6.94m
Enterprise Value $-3.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.13
P/B ratio (TTM) P/B ratio 0.35
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.73m
Free Cash Flow (TTM) Free Cash Flow $-25.75m
Cash position $10.85m
EPS (TTM) EPS $-11.66
P/E forward negative
Short interest 3.87%
Show more

Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Moleculin Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Moleculin Biotech, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Moleculin Biotech, Inc. forecast:

Buy
100%

Financial data from Moleculin Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
46% 46%
-
-0.13 -0.13
46% 46%
-
- Selling and Administrative Expenses 9.21 9.21
14% 14%
-
- Research and Development Expense 18 18
7% 7%
-
-28 -28
10% 10%
-
- Depreciation and Amortization 0.13 0.13
46% 46%
-
EBIT (Operating Income) EBIT -28 -28
10% 10%
-
Net Profit -25 -25
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moleculin Biotech, Inc. Stock News

Neutral
PRNewsWire
5 days ago
Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung cancer models Annamycin continues to be 100% non-cardiotoxic HOUSTON , Sept. 23, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasd...
Neutral
PRNewsWire
11 days ago
Wally Klemp, CEO of Moleculin, discusses the Company's recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma Watch the "What This Means" video here HOUSTON , Sept. 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad por...
Neutral
PRNewsWire
19 days ago
– Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Funding for study provided by NIH and BrainUp® – Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune memory in glioblastoma animal models HOUSTON , Sept. 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Molecul...
More Moleculin Biotech, Inc. News

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Head office United States
CEO Walter Klemp
Employees 18
Founded 2015
Website www.moleculin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today